Charles River Laboratories International, Inc. (CRL)
NYSE: CRL · IEX Real-Time Price · USD
229.89
-2.80 (-1.20%)
May 2, 2024, 4:00 PM EDT - Market closed
CRL Revenue
In the year 2023, Charles River Laboratories International had annual revenue of $4.13B with 3.86% growth. Revenue in the quarter ending December 30, 2023 was $1.01B, a -7.85% decrease year-over-year.
Revenue (ttm)
$4.13B
Revenue Growth
+3.86%
P/S Ratio
2.87
Revenue / Employee
$189,422
Employees
21,800
Market Cap
11.80B USD
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 30, 2023 | 4.13B | 153.35M | 3.86% |
Dec 31, 2022 | 3.98B | 435.90M | 12.31% |
Dec 25, 2021 | 3.54B | 616.23M | 21.08% |
Dec 26, 2020 | 2.92B | 302.71M | 11.55% |
Dec 28, 2019 | 2.62B | 355.13M | 15.67% |
Dec 29, 2018 | 2.27B | 408.50M | 21.99% |
Dec 30, 2017 | 1.86B | 176.17M | 10.48% |
Dec 31, 2016 | 1.68B | 318.13M | 23.34% |
Dec 26, 2015 | 1.36B | 65.64M | 5.06% |
Dec 27, 2014 | 1.30B | 132.13M | 11.34% |
Dec 28, 2013 | 1.17B | 36.00M | 3.19% |
Dec 29, 2012 | 1.13B | -13.12M | -1.15% |
Dec 31, 2011 | 1.14B | 9.23M | 0.81% |
Dec 25, 2010 | 1.13B | -38.23M | -3.26% |
Dec 26, 2009 | 1.17B | -123.66M | -9.55% |
Dec 27, 2008 | 1.30B | 64.67M | 5.26% |
Dec 29, 2007 | 1.23B | 172.24M | 16.27% |
Dec 30, 2006 | 1.06B | 65.06M | 6.55% |
Dec 31, 2005 | 993.33M | 269.11M | 37.16% |
Dec 25, 2004 | 724.22M | 110.50M | 18.00% |
Dec 27, 2003 | 613.72M | 59.09M | 10.65% |
Dec 28, 2002 | 554.63M | 89.00M | 19.11% |
Dec 29, 2001 | 465.63M | 159.05M | 51.88% |
Dec 30, 2000 | 306.59M | 75.17M | 32.48% |
Dec 25, 1999 | 231.41M | 26.35M | 12.85% |
Dec 26, 1998 | 205.06M | 34.35M | 20.12% |
Dec 27, 1997 | 170.71M | - | - |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
Tenet Healthcare | 20.91B |
DaVita | 12.14B |
Incyte | 3.77B |
Dr. Reddy's Laboratories | 2.99B |
United Therapeutics | 2.50B |
Medpace Holdings | 1.96B |
Insulet | 1.70B |
Sarepta Therapeutics | 1.40B |
CRL News
- 12 hours ago - Charles River Launches Viral Vector Reference Materials to Streamline the Transition to GMP - Business Wire
- 10 days ago - Charles River Laboratories Achieves 100% Renewable Electricity Usage Globally - Business Wire
- 16 days ago - Charles River Laboratories Launches Alternative Methods Advancement Project to Reduce Reliance on Animal Testing - Business Wire
- 20 days ago - Charles River Laboratories Schedules First-Quarter 2024 Earnings Release and Conference Call - Business Wire
- 21 days ago - Charles River and Deciphex Launch Patholytix Foresight, a Transformative AI-Powered Decision Support Tool for Toxicologic Pathology - Business Wire
- 23 days ago - Charles River Announces Rare Disease Gene Therapy Collaboration with Axovia Therapeutics - Business Wire
- 4 weeks ago - Charles River to Perform Plasmid Production for Ship of Theseus - Business Wire
- 4 weeks ago - Charles River Laboratories Showcases Technology-Driven Capabilities at AACR 2024 - Business Wire